AgomAb Therapeutics NV (AGMB) Stock Price, News & Analysis

Agomab Therapeutics NV (AGMB) develops disease-modifying therapeutics for fibro-inflammatory, immunology, and inflammatory diseases. The company is a clinical-stage biopharmaceutical issuer headquartered in Antwerp, Belgium, and its American Depositary Shares trade on the Nasdaq Global Select Market under the symbol AGMB. Each ADS represents one common share of Agomab.

Agomab's research and development model centers on chronic fibrotic indications and therapies designed to target established biological pathways. Its product candidates use small-molecule and antibody approaches, including organ-restricted strategies intended to focus activity in affected tissues. The company describes its program focus as resolving fibro-inflammation and restoring organ function in diseases associated with fibrosis.

The company's disclosed pipeline includes ontunisertib, also known as AGMB-129, and AGMB-447. Ontunisertib is being developed in fibrostenosing Crohn's disease, a fibrotic complication of inflammatory bowel disease. AGMB-447 is an investigational inhaled, lung-restricted small molecule inhibitor of ALK5, also referred to as TGFβR1, in development for idiopathic pulmonary fibrosis. Agomab has reported U.S. composition-of-matter patent coverage for AGMB-447.

As a development-stage biopharmaceutical company, Agomab's operating activity is focused on pre-commercial research and clinical development rather than commercial product sales. Its recurring corporate disclosures address clinical-program progress, intellectual-property protection, regulatory interactions, research and development spending, financing activity, and governance matters. Agomab completed its initial public offering of ADSs in February 2026, establishing AGMB as a publicly traded foreign private issuer in the United States.